Skip to main content

Advertisement

SpringerLink
Log in

Acquired cystic disease-associated renal cell carcinoma: further characterization of the morphologic and immunopathologic features

  • Original Paper
  • Published:
Medical Molecular Morphology Aims and scope Submit manuscript

Abstract

Acquired cystic disease-associated renal cell carcinoma (ACD-RCC) is a subtype of renal cell carcinoma (RCC) with unique morphologic features found exclusively in the background of end-stage renal disease. We analyzed the clinicopathologic features and immumoreactive profiles of 12 cases of ACD-RCC to further characterize this recently recognized entity. Review of histologic slides was performed in conjunction with immunohistochemical staining directed to the contemporary diagnostic antibodies and the putative target therapy-related markers. Histologically, the tumors showed characteristic inter-or intracellular microlumens and eosinophilic tumor cells. Intratumoral hemosiderin deposition and degenerating foamy tumor cells were consistent findings which were not previously described. Immunohistochemically, all the tumors were positive for alpha-methylacyl-CoA-racemase, CD10, pan-cytokeratin, PTEN (phosphatase and tensin homolog deleted on chromosome 10) and c-met, while negative for carbonic anhydrase-9, CD57, CD68, c-kit, pax-2, platelet-derived growth factor receptor (PDGFR)-α or vascular endothelial growth factor receptor (VEGFR)-2. Heterogenous staining was found for CK7 and kidney-specific cadherin. Positive reaction to c-met suggests its utility as a plausible therapeutic target in ACD-RCC. Thus, we present the unique morphologic and immunopathologic features of ACD-RCC, which may be helpful in both diagnostic and therapeutic aspects.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Hughson MD, Schmidt L, Zbar B, Daugherty S, Meloni AM, Silva FG, Sandberg AA (1996) Renal cell carcinoma of end-stage renal disease: a histopathologic and molecular genetic study. J Am Soc Nephrol 7:2461–2468

    PubMed  CAS  Google Scholar 

  2. Tickoo SK, dePeralta-Venturina MN, Harik LR, Worcester HD, Salama ME, Young AN, Moch H, Amin MB (2006) Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumor-bearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol 30:141–153

    Article  PubMed  Google Scholar 

  3. Nouh MA, Kuroda N, Yamashita M, Hayashida Y, Yano T, Minakuchi J, Taniguchi S, Nomura I, Inui M, Sugimoto M, Kakehi Y (2009) Renal cell carcinoma in patients with end-stage renal disease: relationship between histological type and duration of dialysis. BJU Int 105:620–627

    Article  PubMed  Google Scholar 

  4. Bhatnagar R, Alexiev BA (2012) Renal-cell carcinomas in end-stage kidneys: a clinicopathological study with emphasis on clear-cell papillary renal-cell carcinoma and acquired cystic kidney disease-associated carcinoma. Int J Surg Pathol 20:19–28

    Article  PubMed  Google Scholar 

  5. Sule N, Yakupoglu U, Shen SS, Krishnan B, Yang G, Lerner S, Sheikh-Hamad D, Truong LD (2005) Calcium oxalate deposition in renal cell carcinoma associated with acquired cystic kidney disease: a comprehensive study. Am J Surg Pathol 29:443–451

    Article  PubMed  Google Scholar 

  6. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, Baum CM, Michaelson MD (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516–2524

    Article  PubMed  CAS  Google Scholar 

  7. Linehan WM, Bratslavsky G, Pinto PA, Schmidt LS, Neckers L, Bottaro DP, Srinivasan R (2010) Molecular diagnosis and therapy of kidney cancer. Annu Rev Med 61:329–343

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  8. Stewart GD, O’Mahony FC, Powles T, Riddick AC, Harrison DJ, Faratian D (2011) What can molecular pathology contribute to the management of renal cell carcinoma? Nat Rev Urol 8:255–265

    Article  PubMed  CAS  Google Scholar 

  9. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) Targeting MET in cancer: rationale and progress. Nat Rev Cancer 12:89–103

    Article  PubMed  CAS  Google Scholar 

  10. Giubellino A, Linehan WM, Bottaro DP (2009) Targeting the Met signaling pathway in renal cancer. Expert Rev Anticancer Ther 9:785–793

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Konda R, Sato H, Hatafuku F, Nozawa T, Ioritani N, Fujioka T (2004) Expression of hepatocyte growth factor and its receptor C-met in acquired renal cystic disease associated with renal cell carcinoma. J Urol 171:2166–2170

    Article  PubMed  CAS  Google Scholar 

  12. Rioux-Leclercq NC, Epstein JI (2003) Renal cell carcinoma with intratumoral calcium oxalate crystal deposition in patients with acquired cystic disease of the kidney. Arch Pathol Lab Med 127:E89–E92

    PubMed  Google Scholar 

  13. Wang S, Filipowicz EA, Schnadig VJ (2001) Abundant intracytoplasmic hemosiderin in both histiocytes and neoplastic cells: a diagnostic pitfall in fine-needle aspiration of cystic papillary renal-cell carcinoma. Diagn Cytopathol 24:82–85

    Article  PubMed  CAS  Google Scholar 

  14. Pardo-Mindan FJ, Diez J, Esparza N, Robledo C (1990) Renal siderosis in patients with heart-valve prostheses: clinical implications. Nephrol Dial Transplant 5:847–850

    Article  PubMed  CAS  Google Scholar 

  15. Jaffar R, Mohanty SK, Khan A, Fischer AH (2009) Hemosiderin laden macrophages and hemosiderin within follicular cells distinguish benign follicular lesions from follicular neoplasms. Cytojournal 6:3

    Article  PubMed  PubMed Central  Google Scholar 

  16. Choi JS, Kim MK, Seo JW, Choi YL, Kim DH, Chun YK, Ko YH (2006) MET expression in sporadic renal cell carcinomas. J Korean Med Sci 21:672–677

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  17. Enoki Y, Katoh G, Okabe H, Yanagisawa A (2010) Clinicopathological features and CD57 expression in renal cell carcinoma in acquired cystic disease of the kidneys: with special emphasis on a relation to the duration of haemodialysis, the degree of calcium oxalate deposition, histological type, and possible tumorigenesis. Histopathology 56:384–394

    Article  PubMed  Google Scholar 

  18. Kuroda N, Ohe C, Mikami S, Hes O, Michal M, Brunelli M, Martignoni G, Sato Y, Yoshino T, Kakehi Y, Shuin T, Lee GH (2011) Review of acquired cystic disease-associated renal cell carcinoma with focus on pathobiological aspects. Histol Histopathol 26:1215–1218

    PubMed  CAS  Google Scholar 

  19. Kuroda N, Shiotsu T, Hes O, Michal M, Shuin T, Lee GH (2011) Acquired cystic disease-associated renal cell carcinoma with gain of chromosomes 3, 7, and 16, gain of chromosome X, and loss of chromosome Y. Med Mol Morphol 43:231–234

    Article  Google Scholar 

  20. Pan CC, Chen YJ, Chang LC, Chang YH, Ho DM (2009) Immunohistochemical and molecular genetic profiling of acquired cystic disease-associated renal cell carcinoma. Histopathology 55:145–153

    Article  PubMed  Google Scholar 

  21. Kuroda N, Tamura M, Hamaguchi N, Mikami S, Pan CC, Brunelli M, Martignoni G, Hes O, Michal M, Lee GH (2011) Acquired cystic disease-associated renal cell carcinoma with sarcomatoid change and rhabdoid features. Ann Diagn Pathol 15:462–466

    Article  PubMed  Google Scholar 

  22. Inoue T, Matsuura K, Yoshimoto T, Nguyen LT, Tsukamoto Y, Nakada C, Hijiya N, Narimatsu T, Nomura T, Sato F, Nagashima Y, Kashima K, Hatakeyama S, Ohyama C, Numakura K, Habuchi T, Nakagawa M, Seto M, Mimata H, Moriyama M (2012) Genomic profiling of renal cell carcinoma in patients with end-stage renal disease. Cancer Sci 103:569–576

    Article  PubMed  CAS  Google Scholar 

  23. Yamaguchi T, Kuroda N, Kawada T, Imamura Y (2012) Imprint cytological findings of acquired cystic disease-associated renal-cell carcinoma: a close relationship to papillary renal-cell carcinoma. Diagn Cytopathol 40:844–846

    Article  PubMed  Google Scholar 

  24. Ljungberg B, Cowan NC, Hanbury DC, Hora M, Kuczyk MA, Merseburger AS, Patard JJ, Mulders PF, Sinescu IC (2010) EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 58:398–406

    Article  PubMed  Google Scholar 

  25. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009) NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 7:618–630

    PubMed  CAS  Google Scholar 

  26. Yuasa T, Takahashi S, Hatake K, Yonese J, Fukui I (2011) Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer. Cancer Sci 102:1949–1957

    Article  PubMed  CAS  Google Scholar 

  27. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S (2010) Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int 106:772–778

    Article  PubMed  CAS  Google Scholar 

  28. Paule B, Bastien L, Deslandes E, Cussenot O, Podgorniak MP, Allory Y, Naimi B, Porcher R, de La Taille A, Menashi S, Calvo F, Mourah S (2010) Soluble isoforms of vascular endothelial growth factor are predictors of response to sunitinib in metastatic renal cell carcinomas. PLoS ONE 5:e10715

    Article  PubMed  PubMed Central  Google Scholar 

  29. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Staehler M, Negrier S, Chevreau C, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Anderson S, Hofilena G, Shan M, Pena C, Lathia C, Bukowski RM (2009) Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol 27:3312–3318

    Article  PubMed  CAS  Google Scholar 

  30. Pantuck AJ, Seligson DB, Klatte T, Yu H, Leppert JT, Moore L, O’Toole T, Gibbons J, Belldegrun AS, Figlin RA (2007) Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer 109:2257–2267

    Article  PubMed  CAS  Google Scholar 

  31. Inoue H, Nonomura N, Kojima Y, Shiba M, Oka D, Arai Y, Nakayama M, Takayama H, Nishimura K, Mori H, Okuyama A (2007) Somatic mutations of the von Hippel–Lindau disease gene in renal carcinomas occurring in patients with long-term dialysis. Nephrol Dial Transplant 22:2052–2055

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Korean Society of Pathologists.

Conflict of interest

The authors declare that there is no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong, Gangnam-gu, Seoul, 135-710, Korea

    Soomin Ahn & Ghee Young Kwon

  2. Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

    Yong Mee Cho

  3. Department of Pathology, Incheon St. Mary’s Hospital, Catholic University of Korea College of Medicine, Incheon, Korea

    Sun-Young Jun

  4. Department of Pathology, Chonnam National University Medical School, Chonnam, Korea

    Chan Choi

  5. Department of Pathology, Sanggye Paik Hospital, Inje Univerisity, Seoul, Korea

    Hyun-Jung Kim

  6. Department of Pathology, Guri Hospital, Hanyang University, Guri, Gyeonggi-do, Korea

    Yong Wook Park

  7. Department of Pathology, National Cancer Center, Goyang, Gyeonggi-do, Korea

    Weon Seo Park

  8. Department of Pathology, Hangang Sacred Heart Hospital, Seoul, Korea

    Jung Won Shim

Authors
  1. Soomin Ahn
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ghee Young Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yong Mee Cho
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sun-Young Jun
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chan Choi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hyun-Jung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yong Wook Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Weon Seo Park
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jung Won Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ghee Young Kwon.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ahn, S., Kwon, G.Y., Cho, Y.M. et al. Acquired cystic disease-associated renal cell carcinoma: further characterization of the morphologic and immunopathologic features. Med Mol Morphol 46, 225–232 (2013). https://doi.org/10.1007/s00795-013-0028-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00795-013-0028-x

Keywords

Search

Navigation